|
1. A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 antibody and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma, wherein administering comprises a monotherapy period with said peptide followed by a combination therapy with said peptide, said anti PD-1 antibody and said chemotherapy, wherein said subject is post first-line treatment against said metastatic pancreatic adenocarcinoma, wherein said chemotherapy comprises irinotecan, fluorouracil (5-FU) and leucovorin (LV), wherein said anti-PD-1 antibody is pembrolizumab and wherein said combination therapy with said chemotherapy and said anti PD-1 is initiated on Day 8, and wherein said first-line treatment comprises a gemcitabine-based chemotherapy.
|